Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2174-2186

  Azizi, Ali ^a,b   Anderson, David E ^a,e   Torres, José V ^a,c   Ogrel, Andrei ^a   Ghorbani, Masoud ^a   Soare, Catalina ^a,b   Sandstrom, Paul ^d   Fournier, Jocelyne ^d   Diaz Mitoma, Francisco ^a,b,f  

^a Variation Biotechnologies Inc   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 PEPTIDE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPIDATED PEPTIDE; NONLIPIDATED PEPTIDE; PEPTIDE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIVE VACCINE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENIC VARIATION; ARTICLE; BIOINFORMATICS; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; GENE SEQUENCE; HETEROLOGOUS EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOREGULATION; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; VACCINIA VIRUS; VIRUS GENE; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CLASSIFICATION; CYTOLOGY; CYTOTOXICITY; IMMUNOLOGY; LIPID METABOLISM; MOLECULAR GENETICS; SYNTHESIS; TRANSGENIC MOUSE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; LIPID METABOLISM; MACACA FASCICULARIS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; VACCINES, ATTENUATED; VACCINES, SUBUNIT;

EID: 42149088946     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2174     Document Type: Article

References (70)

1. Levy, J. A. 2006. HIV pathogenesis: knowledge gained after two decades of research. Adv. Dent. Res. 19: 10-16.
2. Gallo, R. C. 2005. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 366: 1894-1898.
3. Srivastava, I. K., J. B. Ulmer, and S. W. Barnett. 2004. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines 3: S33-S52.
4. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79: 10108-10125.
5. Sarmati, L., G. d'Ettorre, E. Nicastri, L. Ercoli, I. Uccella, P. Massetti, S. G. Parisi, V. Vullo, and M. Andreoni. 2001. Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment. Clin. Diagn. Lab. Immunol. 8: 822-824.
6. Locher, C. P., R. M. Grant, E. A. Collisson, G. Reyes-Teran, T. Elbeik, J. O. Kahn, and J. A. Levy. 1999. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Hum. Retroviruses 15: 1685-1689.
7. Kwong, P. D., R. Wyatt, S. Majeed, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold. Des. 8: 1329-1339.
8. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
9. Kandathil, A. J., S. Ramalingam, R. Kannangai, S. David, and G. Sridharan. 2005. Molecular epidemiology of HIV. Indian J. Med. Res. 121: 333-344.
10. Choisy, M., C. H. Woelk, J. F. Guegan, and D. L. Robertson. 2004. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J. Virol. 78: 1962-1970.
11. Duerr, A., J. N. Wasserheit, and L. Corey. 2006. HIV vaccines: new frontiers in vaccine development. Clin. Infect. Dis. 43: 500-511.
12. Jackson, D. C., Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown. 2004. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101: 15440-15445.
13. Hertz, C. J., S. M. Kiertscher, P. J. Godowski, D. A. Bouis, M. V. Norgard, M. D. Roth, and R. L. Modlin. 2001. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 166: 2444-2450.
14. Duesberg, U., B. A. von dem, C. Kirschning, K. Miyake, T. Sauerbruch, and U. Spengler. 2002. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by Toll like receptors (TLRs) 2 and 4. Immunol. Lett. 84: 89-95.
15. + T cell-immune responses in HLA-A2.1 mice. Curr. HIV Res. 5: 211-219.
16. Azizi, A., M. Ghorbani, M. Kryworuchko, S. Aucoin, and F. Diaz-Mitoma. 2005. Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model. Hum. Vaccin. 1: 170-176.
17. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79: 10108-10125.
18. Poon, B., J. T. Safrit, H. McClure, C. Kitchen, J. F. Hsu, V. Gudeman, C. Petropoulos, T. Wrin, I. S. Chen, and K. Grovit-Ferbas. 2005. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 79: 4927-4935.
19. Jackson, D. C., Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown. 2004. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101: 15440-15445.
20. Hertz, C. J., S. M. Kiertscher, P. J. Godowski, D. A. Bouis, M. V. Norgard, M. D. Roth, and R. L. Modlin. 2001. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 166: 2444-2450.
21. Duesberg, U., A. von dem Bussche, C. Kirschning, K. Miyake, T. Sauerbruch, and U. Spengler. 2002. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by Toll like receptors (TLRs) 2 and 4. Immunol. Lett. 84: 89-95.
22. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
23. + CTL responses. Vaccine 23: 236-246.
24. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
25. Foulds, K. E., C. Y. Wu, and R. A. Seder. 2006. Th1 memory: implications for vaccine development. Immunol. Rev. 211: 58-66.
26. Esser, M. T., R. D. Marchese, L. S. Kierstead, L. G. Tussey, F. Wang, N. Chirmule, and M. W. Washabaugh. 2003. Memory T cells and vaccines. Vaccine 21: 419-430.
27. Puaux, A. L., B. Delache, S. Marconi, M. Huerre, R. Le Grand, Y. Riviere, and M. L. Michel. 2005. Loss of reactivity of vaccine-induced CD4 T cells in immunized monkeys after SIV/HIV challenge. AIDS 19: 757-765.
28. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312: 1530-1533.
29. + T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 176: 5338-5345.
30. Reimann, K. A., R. A. Parker, M. S. Seaman, K. Beaudry, M. Beddall, L. Peterson, K. C. Williams, R. S. Veazey, D. C. Montefiori, J. R. Mascola, et al. 2005. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J. Virol. 79: 8878-8885.
31. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
32. Nyambi, P. N., H. A. Mbah, S. Burda, C. Williams, M. K. Gorny, A. Nadas, and S. Zolla-Pazner. 2000. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 74: 7096-7107.
33. Braibant, M., S. Brunet, D. Costagliola, C. Rouzioux, H. Agut, H. Katinger, B. Autran, and F. Barin. 2006. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 20: 1923-1930.
34. Kothe, D. L., Y. Li, J. M. Decker, F. Bibollet-Ruche, K. P. Zammit, M. G. Salazar, Y. Chen, Z. Weng, E. A. Weaver, F. Gao, et al. 2006. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352: 438-449.
35. Gao, F., E. A. Weaver, Z. Lu, Y. Li, H. X. Liao, B. Ma, S. M. Alam, R. M. Scearce, L. L. Sutherland, J. S. Yu, et al. 2005. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J. Virol. 79: 1154-1163.
36. +-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J. Virol. 76: 12603-12610.
37. + T cell dynamics during primary simian immunodeficiency virus infection in macaques: relationship of effector cell differentiation with the extent of viral replication. J. Immunol. 174: 6898-6908.
38. Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, et al. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102: 1758-1765.
39. Jackson, D. C., Y. F. Lau, T. Le, A. Suhrbier, G. Deliyannis, C. Cheers, C. Smith, W. Zeng, and L. E. Brown. 2004. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA 101: 15440-15445.
40. Espuelas, S., A. Roth, C. Thumann, B. Frisch, and F. Schuber. 2005. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells. Mol. Immunol. 42: 721-729.
41. + T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22: 684-694.
42. Yang, O. O., P. T. Sarkis, A. Ali, J. D. Harlow, C. Brander, S. A. Kalams, and B. D. Walker. 2003. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J. Exp. Med. 197: 1365-1375.
43. Friedrich, T. C., and D. I. Watkins. 2005. The role of the SIV model in AIDS vaccine research. IAVI Rep. 9: 1; 6-1: 8.
44. + T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J. Virol. 73: 4447-4451.
45. Villefroy, P., F. Letourneur, Z. Coutsinos, L. Mortara, C. Beyer, H. Gras-Masse, J. G. Guillet, and I. Bourgault-Villada. 2006. SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251. Virol. J. 3: 65.
46. Carlos, M. P., D. E. Anderson, M. B. Gardner, and J. V. Torres. 2000. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 16: 153-161.
47. Nabel, G. J. 2005. Immunology: close to the edge: neutralizing the HIV-1 envelope. Science 308: 1878-1879.
48. + T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ. Virus Res. 105: 11-22.
49. Zhan, X., L. N. Martin, K. S. Slobod, C. Coleclough, T. D. Lockey, S. A. Brown, J. Stambas, M. Bonsignori, R. E. Sealy, J. L. Blanchard, and J. L. Hurwitz. 2005. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23: 5306-5320.
50. + T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J. Immunol. 177: 5668-5675.
51. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
52. + CTLs ex vivo. J. Immunol. 168: 5954-5958.
53. + T cell memory by short-term IL-4 exposure during T cell receptor stimulation. Proc. Natl. Acad. Sci. USA 97: 3406-3411.
54. Robinson, H. L., and R. R. Amara. 2005. T cell vaccines for microbial infections. Nat. Med. 11: S25-S32.
55. Esser, M. T., R. D. Marchese, L. S. Kierstead, L. G. Tussey, F. Wang, N. Chirmule, and M. W. Washabaugh. 2003. Memory T cells and vaccines. Vaccine 21: 419-430.
56. + T-cell approach feasible? Nat. Rev. Immunol. 2: 283-291.
57. Harari, A., F. Vallelian, and G. Pantaleo. 2004. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur. J. Immunol. 34: 3525-3533.
58. + T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 176: 5338-5345.
59. Letsch, A., U. Keilholz, F. Kern, A. M. Asemissen, E. Thiel, and C. Scheibenbogen. 2006. Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides. J. Immunother. 29: 201-207.
60. Kaul, R., D. Trabattoni, J. J. Bwayo, D. Arienti, A. Zagliani, F. M. Mwangi, C. Kariuki, E. N. Ngugi, K. S. MacDonald, T. B. Ball, et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13: 23-29.
61. Zhang, H., Y. Huang, R. Fayad, G. T. Spear, and L. Qiao. 2004. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J. Virol. 78: 8342-8348.
62. Horner, A. A., S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N. Cinman, M. D. Nguyen, J. H. Van Uden, J. A. Berzofsky, D. D. Richman, and E. Raz. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167: 1584-1591.
63. Plantier, J. C., P. S. Le, F. Poisson, L. Buzelay, B. Lejeune, and F. Barin. 1998. Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J. Virol. 72: 677-683.
64. Rose, N. F., P. A. Marx, A. Luckay, D. F. Nixon, W. J. Moretto, S. M. Donahoe, D. Montefiori, A. Roberts, L. Buonocore, and J. K. Rose. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106: 539-549.
65. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
66. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
67. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
68. Feinberg, M. B., and J. P. Moore. 2002. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8: 207-210.
69. + T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. USA 101: 12324-12329.
70. Reimann, K. A., R. A. Parker, M. S. Seaman, K. Beaudry, M. Beddall, L. Peterson, K. C. Williams, R. S. Veazey, D. C. Montefiori, J. R. Mascola, et al. 2005. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J. Virol. 79: 8878-8885.